Compare AbbVie Inc (ABBV) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? AbbVie Inc trades at $248.5 (market cap $441.94B), while Global X Robo Global Robotics & Automation ETF trades at $84.05. The key difference: AbbVie Inc pays a 2.77% dividend while Global X Robo Global Robotics & Automation ETF pays none. Which is the better fit depends on your goals.
| ABBV | ROBO | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $90.34 |
52-Week Low | $197.38 | $62.34 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
ROBO trades at $84.44, up 1.65% with bullish momentum from moving averages and a neutral oscillator stance. Recent news highlights robotics sector strength, with thematic ETFs gaining attention for AI infrastructure exposure. The stock faces resistance near $85, with support at $84.
Outlook remains positive due to AI-driven demand, but overbought RSI signals caution. Risks include cyclical exposure and valuation concerns. Analysts favor long-term growth, yet near-term volatility may test recent gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
